Kim Tae-Hwan, Lee Mi Yeon, Jin Sung Min, Lee Sang Hyuk
Department of Otorhinolaryngology-Head and Neck Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Division of Biostatistics, Department of R&D Management, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Endocr Relat Cancer. 2022 Oct 7;29(12):635-644. doi: 10.1530/ERC-22-0094. Print 2022 Dec 1.
The impact of serum thyroid hormone levels on thyroid cancer risk is unclear. Some studies reported that elevated thyroid-stimulating hormone (TSH) is associated with higher risk for incidence of thyroid cancer, but other studies reported no relationship. We conducted a large cohort study in 164,596 South Korean men and women who were free of thyroid cancer at baseline and underwent health examination with hormone levels of thyroid function. A parametric proportional hazard model was used to evaluate the adjusted hazard ratio (HR) and 95% CI. During 2,277,749.78 person-years of follow-up, 1280 incident thyroid cancers were identified (men = 593, women = 687). Among men, the multivariable-adjusted HR (95% CI) for thyroid cancer comparing low levels of TSH with normal levels of TSH was 2.95 (1.67-5.23), whereas the corresponding HR (95% CI) in women was 1.5 (0.88-2.55). High levels of free T4 and free T3 were also associated with incident thyroid cancer in both men and women. In clinical implication, overt hyperthyroidism is associated with thyroid cancer in both men and women. Within the euthyroid range, the highest tertile of TSH was associated with a lower risk of thyroid cancer than the lowest TSH tertile and the highest FT4 tertile was associated with a higher risk of thyroid cancer than the lowest FT4 tertile in both men and women. Our finding indicates that low levels of TSH and high levels of FT4, even within the normal range, were associated with an increased risk of incident thyroid cancer.
血清甲状腺激素水平对甲状腺癌风险的影响尚不清楚。一些研究报告称,促甲状腺激素(TSH)升高与甲状腺癌发病风险较高相关,但其他研究则报告无关联。我们对164,596名韩国男性和女性进行了一项大型队列研究,这些人在基线时无甲状腺癌,并接受了甲状腺功能激素水平的健康检查。采用参数化比例风险模型来评估调整后的风险比(HR)和95%置信区间(CI)。在2,277,749.78人年的随访期间,共确诊1280例甲状腺癌(男性 = 593例,女性 = 687例)。在男性中,将低水平TSH与正常水平TSH相比,甲状腺癌的多变量调整后HR(95%CI)为2.95(1.67 - 5.23),而女性中的相应HR(95%CI)为1.5(0.88 - 2.55)。高游离T4和游离T3水平在男性和女性中也均与甲状腺癌发病相关。在临床意义上,明显的甲状腺功能亢进在男性和女性中均与甲状腺癌相关。在甲状腺功能正常范围内,TSH最高三分位数与甲状腺癌风险低于最低TSH三分位数相关,且FT4最高三分位数与甲状腺癌风险高于最低FT4三分位数在男性和女性中均相关。我们的研究结果表明,即使在正常范围内,低水平的TSH和高水平的FT4也与甲状腺癌发病风险增加相关。